Skip to content

Market/Novel Tech

Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial.  This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.

Beacon Therapeutics, based in London and Oxford, UK, have recently announced an investment of £96 million (€112 million) to fund the acquisition of AGTC (Applied… Read More »Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.